We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters (WAT) Boosts LC Solutions Portfolio With New Software
Read MoreHide Full Article
Waters (WAT - Free Report) is leaving no stone unturned to bolster its liquid chromatography (LC) solutions on the back of growing technological capabilities.
In this regard, the company launched the HPLC CONNECT software to integrate its high and ultra-performance liquid chromatography (HPLC/UPLC) systems and multi-angle light-scattering instruments (MALS) into an all-in-one software platform.
The HPLC CONNECT software enhances efficiency, reduces human error and provides accurate size exclusion chromatography (SEC)-MALS analyses for complex biopharmaceutical innovations.
Additionally, the software supports Waters LC systems, allowing users to control HPLC modules from a single dashboard view, and offers optimized SEC columns for biomolecule separation.
Waters is expected to gain solid traction across drug development scientists on the back of its latest launch.
Moreover, it will enable the company to capitalize on growth opportunities present in the global liquid chromatography systems market. Per an MMR report, the global LC systems market is expected to reach $14.45 billion by 2029, witnessing a CAGR of 5.8% between 2023 and 2029.
The latest move is in sync with Waters’ growing efforts to strengthen its Waters Operating segment.
Notably, the company introduced OligoWorks SPE Kits and components for improved sample preparation for LC-mass spectrometry (MS) based bioanalytical quantitation of therapeutic oligonucleotides, offering up to a 2x increase in oligonucleotide recovery from biofluids.
Further, Waters collaborated with the University of San Agustin to equip the latter’s new mass spectrometry imaging center with its advanced technologies.
Per the terms, the MALDI/DESI Mass Spectrometry Imaging Laboratory in the Philippines will be equipped with Waters’ ACQUITY UPLC System and SYNAPT High-Definition Mass Spectrometer technologies, offering effective therapeutics for treating cancer and other infectious diseases through drug discoveries.
Additionally, the company launched the DynaPro ZetaStar instrument for nanoparticle analysis, combining dynamic, static and electrophoretic light scattering measurements, enhancing sensitivity and speed, and utilizing low sample volumes.
Wrapping Up
All the above-mentioned endeavors are expected to aid the company’s Waters Operating segment in the near term. This, in turn, will bolster the overall financial performance of the company.
However, softness in the pharmaceutical, industrial, government and academic markets and unfavorable foreign exchange fluctuations remain major concerns for the company. Its shares have gained 2.6% in the year-to-date period, underperforming the Zacks Medical sector’s growth of 6.3%.
Waters expects first-quarter 2024 total sales to decline in the 8.5-6.5% band on a reported basis.
The Zacks Consensus Estimate for first-quarter 2024 sales is pegged at $633.49 million, indicating a decline of 7.5% from the year-ago quarter.
Image: Bigstock
Waters (WAT) Boosts LC Solutions Portfolio With New Software
Waters (WAT - Free Report) is leaving no stone unturned to bolster its liquid chromatography (LC) solutions on the back of growing technological capabilities.
In this regard, the company launched the HPLC CONNECT software to integrate its high and ultra-performance liquid chromatography (HPLC/UPLC) systems and multi-angle light-scattering instruments (MALS) into an all-in-one software platform.
The HPLC CONNECT software enhances efficiency, reduces human error and provides accurate size exclusion chromatography (SEC)-MALS analyses for complex biopharmaceutical innovations.
Additionally, the software supports Waters LC systems, allowing users to control HPLC modules from a single dashboard view, and offers optimized SEC columns for biomolecule separation.
Waters is expected to gain solid traction across drug development scientists on the back of its latest launch.
Moreover, it will enable the company to capitalize on growth opportunities present in the global liquid chromatography systems market. Per an MMR report, the global LC systems market is expected to reach $14.45 billion by 2029, witnessing a CAGR of 5.8% between 2023 and 2029.
Waters Corporation Price and Consensus
Waters Corporation price-consensus-chart | Waters Corporation Quote
Expanding Waters Operating Segment
The latest move is in sync with Waters’ growing efforts to strengthen its Waters Operating segment.
Notably, the company introduced OligoWorks SPE Kits and components for improved sample preparation for LC-mass spectrometry (MS) based bioanalytical quantitation of therapeutic oligonucleotides, offering up to a 2x increase in oligonucleotide recovery from biofluids.
Further, Waters collaborated with the University of San Agustin to equip the latter’s new mass spectrometry imaging center with its advanced technologies.
Per the terms, the MALDI/DESI Mass Spectrometry Imaging Laboratory in the Philippines will be equipped with Waters’ ACQUITY UPLC System and SYNAPT High-Definition Mass Spectrometer technologies, offering effective therapeutics for treating cancer and other infectious diseases through drug discoveries.
Additionally, the company launched the DynaPro ZetaStar instrument for nanoparticle analysis, combining dynamic, static and electrophoretic light scattering measurements, enhancing sensitivity and speed, and utilizing low sample volumes.
Wrapping Up
All the above-mentioned endeavors are expected to aid the company’s Waters Operating segment in the near term. This, in turn, will bolster the overall financial performance of the company.
However, softness in the pharmaceutical, industrial, government and academic markets and unfavorable foreign exchange fluctuations remain major concerns for the company. Its shares have gained 2.6% in the year-to-date period, underperforming the Zacks Medical sector’s growth of 6.3%.
Waters expects first-quarter 2024 total sales to decline in the 8.5-6.5% band on a reported basis.
The Zacks Consensus Estimate for first-quarter 2024 sales is pegged at $633.49 million, indicating a decline of 7.5% from the year-ago quarter.
Zacks Rank & Stock to Consider
Currently, Waters carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical market sector are DaVita (DVA - Free Report) , Encompass Health (EHC - Free Report) and ICON (ICLR - Free Report) . While DaVita sports a Zacks Rank #1 (Strong Buy) at present, Encompass Health and ICON carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita shares have surged 21.2% in the year-to-date period. DVA’s long-term earnings growth rate is currently projected at 12.15%.
Encompass Health shares have gained 12% in the year-to-date period. EHC’s long-term earnings growth rate is currently projected at 15.35%.
ICON shares have gained 14.2% in the year-to-date period. The long-term earnings growth rate for ICLR is currently projected at 14.90%.